SGLT-2 inhibitors (SGLT-2i) lower blood glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption.
While the relationship between SGLT-2i and breast cancer remains inconclusive, emerging evidence suggests potential anticancer properties.
This systematic review and meta-analysis compares the effects of SGLT-2i and DPP-4i on breast cancer incidence and related mortality to clarify current conflicting evidence.
